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Abstract
Information on specificities of serological responses against tumor cells in cutaneous lymphoma patients is relatively
restricted. To advance the knowledge of serological immune responses against and to assess the scope of tumor
antigenicity of cutaneous lymphoma, 1- and 2-dimensional Western blot analyses with sera from patients were combined
with proteomics-based protein identification. Testing sera from 87 cutaneous lymphoma patients by 1-dimensional Western
blot analysis, 64 cases of seroreactivity against lymphoma cells were found. The positive responses were relatively weak,
restricted to few antigens in each case, and heterogeneous. To identify the antigens, proteins of the mycosis fungoides cell
line MyLa and primary tumor cells were separated by 2-dimensional gel electrophoresis, Western-blotted and probed with
heterogeneous and autologous patient sera. The antigens were identified from silver-stained replica gels by MALDI-TOF
mass spectrometry. 14 different antigens were assigned and identified with this proteome-serological approach. Only one,
vimentin, had been reported before, the other 13 are new antigens for cutaneous lymphomas.
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Introduction
Tumor-associated autoantigens defined by serological immune
responses in cancer patients are of growing interest as potential
biomarkers for disease and targets for therapy [1–8]. The
serological antigenicity of various tumors had mostly been
analyzed by serological identification of recombinant expression
cloning (SEREX) with cDNA libraries of tumor tissue, tumor cells
or cell lines, or of human testis cloned into l phages and expressed
by bacteria [2,9–14]. The cancer-associated autoantigens identi-
fied by this approach can be categorized as differentiation
antigens, cancer-testis antigens, overexpressed gene products,
mutated gene products and cancer-related autoantigens. Some
cancers such as systemic lymphoma, melanoma, colon carcinoma,
head and neck cancer, and renal cancer have been extensively
studied for serological defined antigens (http://www2.licr.org/
CancerImmunomeDB/) [2,10,12–18]. On the other hand, still
limited information on the antigenicity of cutaneous T cell
lymphomas is available [9,10,19–24].
Cutaneous lymphomas are a heterogeneous group of lympho-
proliferative disorders with primary manifestation in the skin
[25,26]. They are usually of low malignancy and evolve over
extended times, often decades. At late stages, however, these
cancers disseminate to lymph nodes, viscera, and bone, and in
some cases develop severe hematological manifestations. High
grade cutaneous lymphomas cause substantial mortality. Al-
though, at earlier stages, the disease can efficiently be managed
with a number of treatment modalities including UV radiation,
cytokines and chemotherapeutics, there is no curative therapy.
Most recently, antibody therapies targeting CD20, CD25 and
CD52 are being tested in clinical trials with promising results [4].
Notwithstanding, long-term observations need to be awaited
before conclusion can be drawn on the effectiveness of these
new therapeutic instruments. Further progress in the development
of these new therapies will depend on the identification of suitable
target molecules. The same is true for diagnosis of cutaneous
lymphomas which relies on clinical, histopathological and
immunohistochemical criteria. As yet, there are no specific
molecular markers for these diseases that could complement and
maybe extend conventional diagnoses. Targets for therapy are not
necessarily restricted to serologically detected antigens but may
also include antigens recognized by T cells and identified through
the analysis of secondary, i.e. T cell-dependent antibody responses.
SEREX has been successfully employed for the identification of
tumor-associated antigens. However, this approach provides no
information on the overall range of the serospecificities in the
individual cases and occurrence of particular serospecificities in
patient populations. Also, antigenicity related to posttranslational
modifications is not detected by this approach. Proteome-based
approaches that combine Western blot analyses of seroreactivities
with mass-spectrometric protein identification can complement
the molecular genetic approaches in these aspects. Proteome
serology makes extensive use of the human genome sequence
database for rapid identification of the serologically detected
antigens. It has been applied to cancers such as renal cell
carcinoma, ovarian cancer, pancreatic adenocarcinoma, prostate
cancer, gastric cancer, lung squamous carcinoma and melanoma
as well as infectious diseases [27–40]. We report here the results of
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8376a first proteome-serological analysis of the antigenicity of
cutaneous lymphoma and the identification of new lymphoma-
associated antigens using this technology.
Results
Seroreactivities to Cutaneous Lymphoma-Associated
Antigens
To determine the frequencies of seroreactivity against and the
scope of the serospecificities for tumor cells in cutaneous
lymphoma, and to identify specificities recurring in different
patients we scanned the sera of 87 patients with cutaneous
lymphoma by 1-dimensional Western blot analyses. All patients
had been diagnosed unequivocally for cutaneous lymphoma by the
clinical, histopathological, immunohistochemical and molecular
genetic criteria of the EORTC/WHO classification [25] (see
Table S1 for details). As protein source, the mycosis fungoides cell
line MyLa was used thus focusing the search on shared antigens
[42]. The cells were solubilized with SDS, solubilisates cleared of
debris, separated by SDS-PAGE and blotted onto nitrocellulose.
The Western blots were then probed with sera of patients with
mycosis fungoides (Figure 1A and B) or other types of cutaneous
lymphoma (Figure 1C–H) or control sera from healthy donors
(Figure 1I). Overall, the signals were relatively weak despite high
serum concentrations used for the Western blots. A large number
of faint bands were detected with the sera of the healthy controls
and patients alike. Notwithstanding, with 64 of the 87 patient sera
relatively prominent signals were detected that were clearly
stronger and in large parts different from those seen with the
healthy control sera. Between 1 (e.g. sera 26 and 39) and 6 (e.g.
sera 12 and 23) such prominent bands were detectable with the
active sera. With two of the healthy control sera a weak band was
indicated at the same migration position in the gel. The patterns of
the detected antigen bands are heterogeneous with no two sera
detecting the same set of antigens and seropositivity for a specific
antigen band restricted to up to not more than 3 sera. The masses
of the detected antigens ranged between 21 and 90 kDa with the
majority of the stronger bands between 40 and 80 kDa.
Comparing frequencies and patterns of seroreactivities with the
diagnosed type of cutaneous lymphoma, no correlation was found,
viz. seropositivity was found with similar frequencies and similarly
heterogeneous specificity pattern for all the tumor entities tested,
and for B and T cell lymphomas alike. In summary, a large
fraction of the patients had developed prominently detectable
antibody responses against antigens of the cutaneous T cell
lymphoma line tested; the serospecificity patterns were heteroge-
neous with no antigen inducing responses in a large fraction of the
patients.
Identification of MyLa-Associated Antigens Detected by
Sera of Cutaneous Lymphoma Patients
The identification of antigens from 1-dimensional SDS-PAGE
gels is complicated by the complexity of the protein mixtures at
every position of the lanes and difficulties in aligning Western blots
with silver-stained gels. We, therefore, separated the proteins of
the MyLa tumor cell line by 2-dimensional electrophoresis with a
pH gradient of 3 to 10 in the isoelectric focusing gels. Five replicas
of these 2-dimensional electrophoresis gels with MyLa proteins
were prepared, 4 were used for Western blot analyses (Figure 2,
panels A–D) and one was silver-stained (Figure 2E). Two of the
nitrocellulose filters were incubated successively with 8 different
patient sera each, so to grasp as many antigens as possible and to
guarantee that every Western blot displayed several antigen spots
which is essential for spot pattern recognition and alignment of
silver-stained proteins with Western blot spots. The sera for
multiple probing were 1, 4, 5, 7, 8, 9, 11 and 12 for the blot shown
with Figure 2A and 14, 18, 19, 20, 21, 22, 23 and 24 for Figure 2B.
The two Western blots shown in Figure 2C and D were probed
with the serum 24 and 12, respectively, alone. Altogether 16
patient sera that had shown reactivity in the 1-dimensional
Western blot analyses were used for the identification of antigens
in the 2-dimensional Western blots. As it was the case for the 1-
dimensional Western blots, the antigen signals were weak but
clearly detectable in the 2-dimensional Western blots. The western
blots shown in Figure 2, panels A–D display 29, 12, 4 and 11
antigen spots, respectively (Table 1). These antigens correspond in
numbers and mass distribution with the antigenicity patterns seen
in the 1-dimensional Western blots (Figure 1). 27 antigens could be
assigned to protein spots in the silver-stained gels (indicated with
arrows in Figure 2). The antigen-protein assignments were done
by first aligning gel and Western blots by their geometry and then
by comparing the spot pattern in the local environments of the
antigens taking spot sizes and shapes into consideration. The thus
identified antigen spots were excised from the gel, destained and
digested with trypsin. The resulting tryptic fragments were
subjected to peptide mass fingerprint analysis by MALDI-TOF-
MS and MASCOT analysis of the mass lists. 7 of the 22 assigned
antigens could thereby be identified. The fingerprint mass spectra
obtained for these antigens are shown in Figure 3. One antigen
was identified twice in two different Western blots. In all cases the
assignment of the mass spectra to the database entries is
unequivocal. In the remaining cases (not shown here), the mass
spectra provided insufficient information for protein identification.
The antigen spots 3, 6, 8, 9 and 15 were identified as the
endoplasmic chaperone BiP, the cytosolic heat shock protein HSP
71, b-tubulin, the b subunit of a mitochondrial ATP synthetase
and TIP47 (a mannose 6 phosphate-binding protein), respectively.
Spots 5 and 7 both were the heat shock protein HSP 60. These
antigens are summarized in Table 2 together with their protein-
chemical parameter, the fractions of assigned masses, sequence
coverage and gene bank accession numbers.
Identification of Cutaneous Lymphoma-Associated
Antigens with Autologous Sera
In three cases, patients 85, 86 and 87 (corresponding to the sera
with the same numbers), tumor materials and sera were obtained
so that the antigenicity of tumor cells could be analyzed with
autologous sera. The tumor cells for the 2-dimensional electro-
phoreses were isolated from freshly excised cutaneous tumor
nodules with ferromagnetic beads and antibodies with specificity
for the T cell receptor (TCR) V b family of the tumor cells. The
cell preparations contained more than 95% tumor cells as
determined by size and TCR Vb measured by flow cytometry
(data not shown). The identities of the tumor cells were confirmed
by PCRs for the tumor-specific TCR Vc rearrangements (not
shown). The protein extracts of each of the 3 tumor cell
preparations were separated by two 2-dimensional electrophoresis
with a pH-range of 3–10. Two replica gels for each sample were
prepared, one each silver-stained and the other used for Western
blot analysis with the autologous sera. In all three cases antigen
spots were detected (Figure 4, Table 1). Figure 4 panels A and B,
and D and E show Western blots for patients 85 and 86,
respectively, and panels C and F the corresponding silver-stained
gels. The antigen signals in the Western blots were very weak in
both cases (Figure 4A and D) and clearly visible only after
enhancement of the readings (Figure 4B and E). Nonetheless,
detections were clear. 1796 proteins were counted in the silver-
stained gel for the tumor cells of patient 85 (Figure 4C) and 1714
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corresponding Western blots displayed 38 antigens for patient 85
(Figure 4A, B) and 12 antigens for patient 86 (Figure 4D, E). All 12
antigens of the tumor cells of patient 86 could be assigned to
protein spots in the silver-stained gel. In the case of patient 85, 13
of the 38 detected antigens could be assigned to protein spots. For
the tumor of patient 87, 3 antigens were detected, but none of
them could be assigned to the corresponding silver-stained gel
(data not shown). The assigned protein spots are indicated with
arrows in the Western blots and silver-stained gels in Figure 4.
They were picked treated with trypsin and the resulting fragments
analyzed by mass spectrometry (Figure 5). The peptide mass
fingerprints were processed with MASCOT for identification of
the antigens. Nine of the 12 assigned antigens of the tumor cells of
Figure 1. Pattern of seroreactivities of cutaneous lymphoma patients against the mycosis fungoides cell line MyLa. Total protein
extract of the tumor cells were separated by SDS-PAGE, blotted onto nitrocellulose and probed with the sera of the patients or of healthy control
donors. The patients were diagnosed for mycosis fungoides (A male, B female), lymphomatoid papulosis (C), pleomorphic cutaneous T cell
lymphoma (D), follicle center cell lymphoma (E), other cutaneous T cell lymphoma (F): CD30+ large cell lymphoma (sera 4, 65 and 84), cytotoxic
cutaneous T cell lymphomas (sera 32 and 52), small cell to medium size cell T cell lymphoma (serum 56), CD8+ epidermotropic cytotoxic cutaneous T
cell lymphoma (serum 78), parapsoriasis (serum 83) and Sezary syndrome (serum) 18) and other B cell lymphomas (G): diffuse large cell B cell
lymphoma (sera 17 and 48), large cell B cell lymphoma (serum 24), mantle cell lymphoma (sera 23, 45 and 71), leukemia (serum 82) and one not
specified B cell lymphoma (serum 29), not specified cutaneous lymphomas (H). The lanes marked with an arrow were rated as seropositive. As
controls, sera of healthy donors were used (I). The numbers atop of each lane represent the numbers of the sera used and correspond to the patient
numbering in Table S1. This numbering is used throughout this report.
doi:10.1371/journal.pone.0008376.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8376Figure 2. Seroreactivities of patients with cutaneous lymphoma against the mycosis fungoides cell line MyLa. Total protein extracts of
MyLa cells were separated by 2-dimensional electrophoresis with an isoelectric focusing pH range of 3–10 in the first and SDS-PAGE in the second
dimension, blotted onto nitrocellulose membranes and probed with the sera of the patients as listed in Table 1. Serum dilutions were 1/200. The
blots A and B were probed with 8 different sera each, blots C and D with single sera. Antigens were detected in the boxed regions of the gels. The
antigen signals were very weak although high concentrations of the sera were used which caused a relatively high background of the blots. To
enhance the visibility of the spots, the contrast of the image areas around the spots was intensified. For every Western blot analysis A through D, the
original is shown on the left and the regions with the enhanced spots for the regions indicated with Roman numerals on the right. A silver-stained gel
of the MyLa proteome corresponding to the Western blots A–D is shown in E. The antigen spots that could be assigned to protein spots in the silver-
stained gel are indicated with arrows and numbered.
doi:10.1371/journal.pone.0008376.g002
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identified. The respective peptide mass fingerprints are shown in
Figure 5 with the masses that were matched to the theoretical
spectra for the identified proteins marked with asterisks. Lamin B1
was found for both patients (spot 8). Vimentin was found 13-times
in different antigen spots (spots # 9), 7-times for patient 85 and 6-
times for patient 86. For these two proteins only 1 representative
mass spectrum each is shown. In addition to these two, b-tubulin
and coronin were found as antigens of the tumor cells of patient 86
(antigen spots 2 and 3, respectively, in Figure 4D–F). In the case of
patient 85, aconitase (antigen 1), the glutamate dehydrogenase
(antigen spot 4), keratin 16 (antigen spot 5), lamin A/C isoform 1
(antigen spot 6) and lamin A/C isoform 2 (antigen spot 7) were
identified, all represented by a single antigen spot. The statistics for
antigen identification is listed in Table 1 and the antigens, their
protein-chemical characteristics, mass spectrometric sequence
coverage, numbers of assigned tryptic fragments, and gene bank
accession numbers together with the respective data for the MyLa-
associated antigens in Table 2.
Discussion
In all, about 160 antigens were detected in 1-dimensional
Western blots with sera of 87 cutaneous lymphoma patients of
whom 64 displayed a specific reactivity against at least 1 tumor-
associated antigen. In average, each patients had developed
specific antibody responses to 2 antigens. Some of the specific
antigen bands were detected with sera of different patients but no
two patients displayed the same pattern of antigenicity. In highly
resolving 2-dimensional Western blots 109 antigen spots were
detected with sera of 19 patients, i.e. an average of 5 to 6 per
patient. Fifty-two of these antigens could be assigned to protein
spots in silver-stained gels and 30 identified by the proteome-
serological approach employed here. They were found to
represent 14 different antigens, one, vimentin, was identified as
different variants in 13 different antigen spots, three, HSP 71, HSP
60 and b-tubulin each in 2 independent gels. Two more antigens
were detected with the sera of more than one patient but could not
be assigned to defined spots in the silver-stained gels. In the 3 cases
where the proteomes of tumor cells freshly prepared from tumor
nodules could be tested with autologous sera, two antigens, lamin
B1 and vimentin, were detected with two of the tumor-serum
combinations with otherwise heterogeneous antigenicity patterns.
Shared antigens detected in the autologous combinations of tumor
cell proteomes and sera differ from those found in the heterologous
combinations. Moreover, as judged from the apparent molecular
masses of the antigens detected in the 1D Western blot analyses,
the antigens are not shared among a majority of patients even
when grouped according to diagnoses. The serological immuno-
reactivities against the tumor cells, thus, were heterogeneous in the
1D as well as in the 2D Western blot analyses, and in
heterogeneous combinations against the mycosis fungoides cell
line MyLa and in autologous combinations. This is in contrast to
serological immune responses against foreign antigens as we have
shown for patients with visceral leishmaniasis where a high degree
of shared antigenicity is documented by matching antigen spot
patterns in the 2-D Western blot system [40]. These comparisons
with the high-antigenicity situations for complex infectious agents
also testify to the reproducibility of the proteomics-based
seroanalytics employed in the study presented here. Heterogenicity
of serological anti-tumor immune responses has also been found in
our studies with melanoma patients [36] and is indicated for a
number of other cancers analyzed with the same technology
[27,29,30,32,35,47–55]. For all antigens, the signals in the
Western blots were relatively weak despite high serum concentra-
tions indicating that the magnitudes of B cell responses were low.
Nonetheless, the majority of the patients with cutaneous
lymphoma had mounted antibody responses against antigens of
the tumor cells. Distinctively more antigens were detected in the
autologous combinations of proteomes and sera than in the
heterogeneous suggesting an individualized tumor cell antigenicity.
All the responses were secondary, meaning IgG, responses
Table 1. Summary of the combinations of tumor cells and sera used for mapping the serospecificities of cutaneous lymphoma
patients by 2-dimensional electrophoresis and proteome analyses.
Tumor cells{* Sera{* Number of antigens
#
total detected assigned identified
Heterogeneous combinations
MyLa A:1 ,4 ,5 ,7 ,8 ,9 ,1 1 ,1 2 2 9 1 2 6
MyLa B: 14, 18, 19, 20, 21, 22, 23, 24 12 6 0
MyLa C: 2 4 400
MyLa D:1 2 1 1 9 2
Autologous combinations
Patient 85 85 38 13 13
Patient 86 86 12 12 9
Patient 87 87 3 0 0
Total 109 52 30
{The tumor cells used for the 2-dimensional electrophoreses were either the mycosis fungoides tumor cell line MyLa or tumor cells freshly isolated from tumor lesion of
the indicated patients.
{The sera used to identify tumor-associated antigens by 2-dimensional Western blot analyses were obtained from patients with cutaneous lymphoma. For the
heterogeneous combinations of sera and tumor cells, 8 independent sera each were grouped into two Western blot experiments. In 2 cases single sera were analyzed.
The Western blots A–D are shown in Figure 2.
*The numbering of the sera in this summary is the same as indicated in Figure 1 for the 1-dimensional Western blot analyses and Figures 2–4 for the 2-dimensional
analyses.
#The numbers given for the antigens refer to the indicated Western blot analyses. Some antigens were identified repeatedly for different tumor cells and patients.
doi:10.1371/journal.pone.0008376.t001
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8376Figure 3. Identification of MyLa-associated antigens detected by sera of cutaneous lymphoma patients. The protein spots that could
be assigned to antigen spots were picked from the gels and treated with trypsin. The resulting fragments were analyzed by mass spectrometry to
identify the antigens. Seven different antigens were identified by peptide mass fingerprint analysis as BiP (spot and spectrum 3), HSP60 (spot and
spectrum 5), HSP71 (spot and spectrum 6), HSP60 (spot and spectrum 7), b-tubulin (spot and spectrum 8), the b-subunit of the mt-ATP synthase (spot
and spectrum 9) and TIP47, a mannose 6 phosphate receptor-binding protein (spot and spectrum 15). The peptide mass fingerprint spectra are
numbered according to the antigen spots in Figure 2. The mass peaks marked with an asterisk match the theoretical spectrum of the assigned
proteins. The statistics of the fingerprint analyses is summarized in Table 2.
doi:10.1371/journal.pone.0008376.g003
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MHC class II-restricted CD4
+ helper T cells with specificity for
the same antigens which is prerequisite for the Ig class switch
leading to IgG-type responses.
The categories of proteins identified as antigens were to some
degree different in the heterogeneous and autologous combina-
tions of tumor cells and sera: Most antigens, particular in the
autologous combinations, were structural proteins (b tubulin,
coronin, keratin 16, lamin A, lamin B1, lamin C and vimentin). In
the heterologeous combinations, chaperones (HSP 60, HSP 71
and BiP) were prominent. In both analyses, metabolic enzymes
(aconitase, glutamate dehydrogenase, mitochondrial ATP synthe-
tase, TIP47, a mannose-6-phosphate-binding protein) were found.
Two antigens (aconitase and ATP synthetase) are mitochondrial
proteins and 2 (BiP and TIP47) proteins of export pathways.
Interestingly, keratin 16 was found identified as antigen in
cutaneous lymphoma. Keratin 16 is part of the cytoskeleton in
epithelial cells and up-regulated in wound healing, but normally
not expressed by lymphoid cells. It seems ectopically expressed by
the cutaneous lymphoma cells. Notable is also the antigenicity of
the three nuclear intermediate filament proteins lamin A/C
isoform 1, lamin A/C isoform 2 and lamin B1. The multiplicity of
vimentin may indicate the presence of splice variants and, maybe,
differentially phosphorylated isoforms. The detected antigens are
intracellular proteins, not directly accessible to the immune
system. Their immunogenicity may relate to the turn-over of the
tumor cells and/or destruction of the cells induced by therapeutic
interventions or tumoricidal activities of the immune system. As
the proteome-based approach can also pick up posttranslational
modifications, tumor-related alterations in post-transcriptional
processing of proteins may also result in neo-antigenicity of
otherwise normal cellular proteins.
The proteome serological approach had been used for antigen
discovery for renal cell carcinoma [27,32,47,48], breast cancer
[49], colon carcinoma [50], prostate cancer, pancreatic adeno-
carcinoma [30], ovarian cancer [29], hepatocellular carcinoma
[35,51,52], lung squamous carcinoma [53,54], leukemia [55] and
melanoma [36]. Among the antigens reported for these cancers,
metabolic enzymes are most prominent and the antigenicity of
these autoantigens has been related to their up-regulation in the
tumor cells. Proteins of the cytoskeleton, chaperones and others
were found as well but less often. While the spectrum of the
different classes of antigens reported here for cutaneous lymphoma
is similar, their representation is noticeably different and different
for the heterologous versus the autologous combinations of sera
and proteomes: Four of the 7 antigens identified with the patient
sera in the MyLa proteome were chaperones and 7 of the 9
antigens found in the autologous combinations proteins of the
cytoskeleton, in particular intermediate filament proteins. Similar
to the situation with metabolic enzymes in other cancers, these
proteins may be overexpressed and thereby of increased
immunogenicity. The immunogenicity of keratin 16 may be
related to its ectopic expression. Of the antigens reported herein,
only vimentin had been reported as an antigen in cutaneous
Table 2. Antigens identified for cutaneous lymphoma by proteome serology.
Spot
Nr. Antigen (gene identifier numbers) Mw [kDa] pI Number of masses{
Sequence
coverage
{
Number of
antigen spots
{
total matched
Heterogeneous combinations
3 BiP (gi|6470150) 70.9 5.23 29 24 42% 1
5 HSP 60 (gi|49522865) 61.2 5.70 43 25 48% 1
6 HSP 71 (gi|32467) 70.9 5.37 85 37 50% 2
7 HSP 60 (gi|77702086) 61.2 5.70 48 14 28% 1
8 b tubulin (gi|57209813) 47.7 4.70 39 19 34% 1
9 mt-ATP Synthase, b-subunit (F1 complex) (gi|16741373) 56.5 5.26 35 22 42% 1
15 TIP47 (gi|16306789) 47.0 5.30 32 14 44% 1
Autologous combinations
1 aconitase (gi|20072188) 85.51 7.62 46 25 31% 1
2 b tubulin (gi|567053) 49.70 4.78 57 13 33% 1
3 coronin (gi|5902134) 51.00 6.25 58 18 28% 1
4 glutamate dehydrogenase (gi|20151189) 61.36 7.66 53 27 42% 1
5 keratin 16 (gi|24430192) 51.21 4.99 63 14 30% 1
6 lamin A/C isoform 1 (gi|27436946) 75.00 6.57 61 30 43% 1
7 lamin A/C isoform 2 (gi|5031875) 65.01 6.40 61 40 56% 1
8 lamin B1 (gi|5031877) 66.37 5.13 29–99 24–69- 34–43% 2
9 vimentin (gi|5030431, gi|340234) 35.02–56.55 4.82–5.06 41–95 12–51- 29–74% 13
The antigens are listed with reference to the antigen spot numbers as indicated in Figures 2 and 4, their masses and isoelectric points and the outcomes of the peptide
mass fingerprints analyses.
*The spot numbers refer to the numbering given for the proteome-serological analyses for the heterogeneous and autologous combinations of tumor cells and sera,
respectively.
{The numbers of peaks detected, numbers of peaks assigned and sequence coverage are the results of the peptide mass fingerprint analyses by MASCOT. In case of
TIP47 a number of calculated fragments are di-, tri- or tetrapeptides with masses below 500 Dalton which set as threshold in this case.
{The number of antigen spots refers to all analyses reported herein. Numbers higher than 1 indicate that the same antigen was identified repeatedly in independent
protein spots, some in independent electrophoresis gels, vimentin repeatedly in independent 2 gels.
doi:10.1371/journal.pone.0008376.t002
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[9,10,19–24]. Other antigens so far identified for cutaneous
lymphoma include cTAGE and TSGA10 both of which were
originally classified as cancer-testis antigens as well as a number of
nuclear proteins, proteins of the transcription machinery,
metabolic enzymes and others. For cTAGE, cancer testis-specific
splice variations have been suggested [22]. TSGA10, despite its
naming, is ubiquitously expressed and not restricted to testis
[10,56–58]. We had found HSP60 and aconitase also for
melanoma [36], and HSP 71, vimentin and tubulin had been
reported for other cancers.
The antigens found for the various cancers analyzed so far by
proteome serological analyses and by SEREX show very little
overlap suggesting that these two technologies probe different
categories of antigens and may complement each other for the
elucidation of the antigenicity of tumor cells. As for the potential
use of the identified antigens in cancer immunotherapy or for
cancer diagnostics, none of the antigens identified with the
present study are outer membrane proteins and suited for
antibody-mediated targeted therapy. However, they raise sec-
ondary antibody responses in cancer patients and, thereby, can
guide the identification of epitopes for CD4
+ MHC class II-
restricted helper T cells. So far, only few such epitopes are known
[59]. A large spectrum of epitopes is required for designing
therapeutic vaccines for cancer immunotherapy. The heteroge-
neity of the antibody responses in cancer patients does not suggest
single antigen-based serodiagnostics. However, protein arrays
that probe antibody responses against sets of antigens identified
by SEREX and proteome serology might well be of diagnostic
value.
Materials and Methods
Tumor Cells, Cell Lines and Sera
The tumor cells were isolated from excised skin tumors by
passaging through a cell sieve to remove connective tissue and
MACS with antibodies for the Vb family of the tumor cells as
previously established by immunohistochemistry. By molecular
genetic analysis of the TCR Vc rearrangement, these tumor cell
preparations were homogeneous (data not shown). Flow cytometry
showed that by size and Vb at least 95% of the sorted cells were
tumor cells. The mycosis fungoides tumor cell line MyLa was
grown in DMEM supplemented with 5% fetal calf serum, 5%
newborn calf serum, 30 nM mercaptoethanol, penicillin and
streptomycin at 37uC in a humidified atmosphere with 8% CO2
[41,42]. All cells were processed for electrophoretic analysis
immediately after harvest from cell cultures or collected from the
cell sorter. The sera were collected from 87 patients with
cutaneous lymphoma and 8 healthy donors of the Department
of Dermatology, Charite ´. The clinical background information on
the cutaneous lymphoma patients are listed in Table S1. The study
and the use of materials from human subjects had been reviewed
and approved by the institutional ethics committee of the Charite ´
– Universita ¨tsmedizin Berlin (Si. 277, September 11, 2003). The
Figure 4. Seroreactivities of patients with mycosis fungoides against autologous tumor cells. Protein extracts of tumor cells of patient 85
(panels A–C) and patient 86 (panels D–F) were separated by 2-dimensional electrophoresis with a pH range of 3–10 for isoelectric focusing in the first
and SDS-PAGE in the second dimension. The proteins were blotted onto nitrocellulose and probed with the respective sera (panels A and D)o r
visualized by silver staining in replica gels (panels C and F). Since the antigen reactivities are weak and their visibility further reduced by the high
background which is due to the high serum concentrations that had to be used for antigen detection, the antigen spots were enhanced by image
processing (panels B and E). Antigen spots that could be assigned to protein spots in the silver-stained gels are indicated with arrows and numbered.
doi:10.1371/journal.pone.0008376.g004
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8376Figure 5. Identification of tumor-associated antigen defined by autologous sera. The protein spots assigned to antigens were picked and
treated with trypsin. The peptide mass fingerprints of the resulting protein fragments were determined by mass spectrometry. Twenty-two of the
assigned antigens were identified as aconitase (spot and spectrum 1), b-tubulin (spot and spectrum 2), coronin (spot and spectrum 3), glutamate
dehydrogenase (spot and spectrum 4), keratin 16 (spot and spectrum 5), lamin A (spot and spectrum 6), lamin C (spot and spectrum 7), lamin B1
(spots and spectrum 8) and vimentin (spots and spectrum 9). Lamin B1 was identified in two and vimentin in 13 different spots. Only one
representative spectrum is shown each. The mass peaks marked with an asterisk correspond to peptide masses which were matched to the
theoretical spectrum of the identified protein. The numbers of the spectra corresponds to the numbers of the spots in Figure 4.
doi:10.1371/journal.pone.0008376.g005
Proteome Serology of CT/BCL
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8376materials were obtained and used with written informed consent of
the donors.
Protein Sample Preparation
The cells were harvested by centrifugation at 1,600 x g for 10
minutes at 20uC, washed thrice with PBS and solubilized in lysis
buffer (7 M urea, 2 M thiourea, 2.5% Triton X-100, 2% b-
mercaptoethanol, 0.8% Pharmalyte pH 3,5–10 (LKB, Freiburg,
Germany), 200 mM PefablockH (Merck, Darmstadt), 1 mM
pepstatin (SIGMA, Munich, Germany) and 10 mM leupeptin
(SIGMA, Munich, Germany) as adapted from Go ¨rg [43] and
Chan [44] by vortexing and sonicating in an ice-cooled water bath
for 10 minutes. The cell extracts were then incubated for one hour
at room temperature (RT) with 4,000 U/ml benzonase (Merck,
Darmstadt, Germany) to degrade nucleic acids and centrifuged at
350,000 x g for 15 minutes at 15uC. The supernatants were
collected, incubated once again with Benzonase for 10 minutes at
RT and cleared by ultracentrifugation as before.
Two-Dimensional Gel Electrophoresis (2DE)
Isoelectric focusing (IEF) was done in immobilized pH-gradient
gel strips (IPG strips 18063 mm; Pharmacia, Freiburg) with a pH
range of 3 to 10 [43,44]. Approximately 100 mg protein, i.e. the
extract of 1610
6 cells, in 350 ml solubilization buffer were applied
per IPG strip and loaded overnight at RT by in-gel re-swelling
under silicon oil in nitrogen and water saturated atmosphere to
prevent oxidation of the protein and drying of the gel strips. The
loaded IPG strips were rinsed, mounted on a cooled ceramic plate
and connected with the electrodes via wetted paper bridges to the
electrodes. The IEF was run at 20uC under silicon oil in a
nitrogen- and water-saturated atmosphere. The electric settings
were 0.15 mA per IPG strip and voltage stepwise increased: 18 h
50 V, 1 h 150 V, 2 h 300 V, 1 h 600 V, 6.5 h 3,500 V and 3 h
5,000 V for a total of 40,000 Vh for pH 3–10 IPG strips. After the
run, the IPG-strips were stored at 220uC. For the second
dimension, IPG strips were thawed, rinsed with de-ionized water
and equilibrated to SDS-PAGE sample buffer for 15 minutes (6 M
urea, 30% glycerol, 2% sodium dodecylsulfate (SDS), Tris pH 6.8
and bromophenol blue, 1% dithiothreitol (DTT)) followed by 15
minutes in the same buffer with 4% iodoacetamide instead of
DTT. The equilibrated IPG-strips were rinsed with de-ionized
water and placed gel-side to gel-side onto the 4.8% acryl amide,
0.13% bisacryl amide stacking gel of a horizontal SDS
polyacrylamide gel with a 12.3% acryl amide, 0.34% bisacryl
amide separation gel. The settings for the runs were 1,000 V,
40 W and 20 mA for 2–3 h for transfer of the proteins from the
IPG strip into the SDS polyacrylamide gel, and 1,000 V, 40 W
and 40 mA for the separation until the running front reached the
anodic end of the gel.
Protein Staining
The gels were stained with the high sensitivity silver staining
method by Blum and colleagues [45]. Briefly, SDS-PAGE gels
were fixed in 40% Methanol, 10% acetic acid for one hour. Then,
the gels were washed three times for 20 minutes in de-ionized
water, sensitized for one minute with 0.02% sodium thiosulfate,
washed thrice for 20 seconds in water and incubated for 20
minutes in silver staining solution (0.2% silver nitrate, 0.0074%
formaldehyde). After three washes for 20 seconds in water, gels
were incubated in developing solution (6% sodium carbonate,
0.00015% formaldehyde, 0.0004% sodium thiosulfate) until
protein spots became visible. Reactions were stopped with
0.025% EDTA in water.
Western Blot
Proteins from unstained SDS-PAGE were transferred to
nitrocellulose membranes (Schleicher & Schu ¨ll, Dassel, Germany)
by semi-dry blotting for 2 hours at 400 mA. Free binding sites on
the membranes were blocked with 5% low-fat milk powder in
Tris-buffered saline (TBS) for one hour at room temperature or
overnight at 4uC. After blocking, the membranes were incubated
with patient sera at a 200-fold dilution for one hour at room
temperature, washed thrice for 10 minutes with TBS and
incubated for 30 min with alkaline phosphatase-labelled anti
human IgG (Anti-Human Ig-AP, Fab fragment; Boehringer
Mannheim) at a 5,000-fold dilution. After washing three times
for 10 minutes with TBS, the membranes were equilibrated to
developing buffer (100 mM NaCl, 100 mM Tris-HCl, pH 9.5)
and developed in the dark with 100 ml BCIP and 100 ml NBT in
100 ml developing buffer until antigen spots became visible. The
reactions were stopped with water. For 1-dimensional Western
blots, the proteins were separated by SDS-PAGE, 12% acryl
amide, 0.8% bisacryl amide and blotted for 1 h with 60 mA as
above.
Alignment of Western Blot and Silver-Stained Protein
Spots
For unequivocal alignment of Western blot and silver-stained
spots, first, gels and blots were marked with protein spots from a
pipette tip at cardinal points and aligned according to these spots.
Second, adjustment of the alignments was done according to
marker spots of the electrophoretically separated proteins
identified on the blots after Ponceau S staining. Suitable marker
proteins had previously been determined by partial blotting.
Third, fine-adjustment of the alignments was done according to
the spot pattern in the local environment of the antigens taking
spot sizes and shapes into consideration. This approach, thus,
combines automated pattern recognition with control by visual
editing.
In-Gel Proteolytic Fragmentation of the Proteins
The protein spots were excised manually with spot picker and
de-stained as by Gharadaghi and colleagues [46] with 50 mlo f
Farmer’s reducing solution (15 mM potassium ferricyanide and
50 mM sodium thiosulfate, both dissolved in water) and washed
three times for 5–10 minutes with 150 ml water. Afterwards gel
spots were soaked in acetonitrile and dried in vacuum. Gel pieces
were re-swollen in 7.5 ml of 5 mM ammonium bicarbonate with
75 ng of modified porcine trypsin (sequencing grade, modified;
Promega; Madison, USA) to fragment the protein. After 10
minutes, 7.5 ml of 5 mM ammonium bicarbonate were added and
the solution with the gel pieces incubated for at least 4 hours at
37uC. For MS analysis, 1.5 ml of the aqueous supernatants were
mixed with 1 ml of 2,5-dihydroxybenzoic acid (DHB) (SIGMA,
Munich, Germany) (5 mg/ml water) on MALDI targets (MTP
AnchorChip 600/384, Bruker Daltonik, Bremen) and air-dried.
Mass Spectrometry
Mass spectrometric measurements were done with a Reflex IV
MALDI-TOF mass spectrometer (MS; Bruker Daltonik, Bremen)
in reflector mode at an acceleration voltage of 20 kV. The MS was
calibrated either with the external standards angiotensin II (1046.5
Da), angiotensin I (1296.6 Da), bombesin (1619.8 Da), substance P
(1347.7 Da), ACTH 1–17 (2093.0 Da) and ACTH 18–39 (2465.1
Da) or, as internal standards, with the autolytic trypsin fragments
of 842.50 Da and 2211.10 Da. Monoisotopic peptide masses were
determined. The spectra were processed by the Xmass software
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Post-source decay (PSD) analyses were done in sets of 10 sections
for the entire mass range and data were accumulated from up to
300 shots per section. The peak lists of the mass spectra were used
for peptide mass fingerprint analyses with the Mascot software
(Matrix Science; http:www.matrixscience.com/search_form_
select.html) and profound (prowl; http://prowl.rockefeller.edu/
profound_bin/WebProFound.exe) together with the NCBI
sequence database.
Supporting Information
Table S1 Listing of data of CB/TCL patients whose sera were
tested
Found at: doi:10.1371/journal.pone.0008376.s001 (0.04 MB
PDF)
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